Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

BACKGROUND Previous studies of the prognosis of patients with heart failure due to cardiomyopathy categorized patients according to whether they had ischemic or nonischemic disease. The prognostic value of identifying more specific underlying causes of cardiomyopathy is unknown. METHODS We evaluated the outcomes of 1230 patients with cardiomyopathy. The patients were grouped into the following categories according to underlying cause: idiopathic cardiomyopathy (616 patients), peripartum cardiomyopathy (51); and cardiomyopathy due to myocarditis (111), ischemic heart disease (91), infiltrative myocardial disease (59), hypertension (49), human immunodeficiency virus (HIV) infection (45), connective-tissue disease (39), substance abuse (37), therapy with doxorubicin (15), and other causes (117). Cox proportional-hazards analysis was used to assess the association between the underlying cause of cardiomyopathy and survival. RESULTS During a mean follow-up of 4.4 years, 417 patients died and 57 underwent cardiac transplantation. As compared with the patients with idiopathic cardiomyopathy, the patients with peripartum cardiomyopathy had better survival (adjusted hazard ratio for death, 0.31; 95 percent confidence interval, 0.09 to 0.98), and survival was significantly worse among the patients with cardiomyopathy due to infiltrative myocardial disease (adjusted hazard ratio, 4.40; 95 percent confidence interval, 3.04 to 6.39), HIV infection (adjusted hazard ratio, 5.86; 95 percent confidence interval, 3.92 to 8.77), therapy with doxorubicin (adjusted hazard ratio, 3.46; 95 percent confidence interval, 1.67 to 7.18), and ischemic heart disease (adjusted hazard ratio, 1.52; 95 percent confidence interval, 1.07 to 2.17). CONCLUSIONS The underlying cause of heart failure has prognostic value in patients with unexplained cardiomyopathy. Patients with peripartum cardiomyopathy appear to have a better prognosis than those with other forms of cardiomyopathy. Patients with cardiomyopathy due to infiltrative myocardial diseases, HIV infection, or doxorubicin therapy have an especially poor prognosis.

[1]  S. Yusuf,et al.  Natural history and patterns of current practice in heart failure , 1993 .

[2]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[3]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[4]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[5]  J. Cohn,et al.  Prognosis of congestive heart failure and predictors of mortality. , 1988, The American journal of cardiology.

[6]  S. Rahimtoola,et al.  Natural Course of Peripartum Cardiomyopathy , 1971, Circulation.

[7]  G. Koch,et al.  Gender differences in survival in advanced heart failure. Insights from the FIRST study. , 1999, Circulation.

[8]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[9]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[10]  H. Kay,et al.  Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. , 1987, The American journal of cardiology.

[11]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.

[12]  D. Homans.  Current concepts: peripartum cardiomyopathy , 1985 .

[13]  Mark A. Hlatky,et al.  Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .

[14]  J H Patterson,et al.  Relation between gender, etiology and survival in patients with symptomatic heart failure. , 1996, Journal of the American College of Cardiology.

[15]  P E Leaverton,et al.  Prevalence and mortality rate of congestive heart failure in the United States. , 1992, Journal of the American College of Cardiology.

[16]  G. Berry,et al.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. , 1997, The New England journal of medicine.

[17]  R. Hruban,et al.  The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. , 1999, Medicine.

[18]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[19]  P. Decouflé,et al.  National sources of vital status information: extent of coverage and possible selectivity in reporting. , 1990, American journal of epidemiology.

[20]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[21]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[22]  J. Cohn,et al.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[23]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[24]  G. Hutchins,et al.  The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. , 1994, Journal of the American College of Cardiology.